Top-Rated StocksTop-RatedNASDAQ:INSM Insmed (INSM) Stock Price, News & Analysis $72.87 -0.39 (-0.53%) (As of 09/18/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends About Insmed Stock (NASDAQ:INSM) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Key Stats Today's Range$72.58▼$74.5350-Day Range$70.99▼$79.0152-Week Range$21.92▼$80.53Volume1.49 million shsAverage Volume2.42 million shsMarket Capitalization$10.83 billionP/E RatioN/ADividend YieldN/APrice Target$79.19Consensus RatingBuy Company OverviewInsmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.Read More… This diversified cannabis pioneer could make huge moves soon (Ad)The cannabis industry seems deeply saturated, so how do you know where to best invest your money? Let’s start with diversification and experience. Founded in 2005, this company serves a diverse and expansive customer base with more than 8,000 retail locations, including licensed cannabis dispensaries, smoke shops, and specialty retailers. Learn more here. Insmed Stock Analysis - MarketRank™See Top Rated MarketRank™ StocksOverall MarketRank™: 73rd PercentileInsmed scored higher than 73% of companies evaluated by MarketBeat, and ranked 315th out of 1,014 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.5 / 5Analyst RatingBuy Consensus RatingInsmed has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 16 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageInsmed has been the subject of 12 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Insmed's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Insmed are expected to grow in the coming year, from ($5.42) to ($4.25) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Insmed is -13.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Insmed is -13.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Insmed's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted8.23% of the outstanding shares of Insmed have been sold short.Short Interest Ratio / Days to CoverInsmed has a short interest ratio ("days to cover") of 4.9.Change versus previous monthShort interest in Insmed has recently decreased by 9.41%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldInsmed does not currently pay a dividend.Dividend GrowthInsmed does not have a long track record of dividend growth. Sustainability and ESG4.5 / 5Environmental Score-1.28 Percentage of Shares Shorted8.23% of the outstanding shares of Insmed have been sold short.Short Interest Ratio / Days to CoverInsmed has a short interest ratio ("days to cover") of 4.9.Change versus previous monthShort interest in Insmed has recently decreased by 9.41%, indicating that investor sentiment is improving significantly. News and Social Media2.1 / 5News Sentiment0.78 News SentimentInsmed has a news sentiment score of 0.78. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 13 news articles for Insmed this week, compared to 6 articles on an average week.Search InterestOnly 1 people have searched for INSM on MarketBeat in the last 30 days. This is a decrease of -93% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added Insmed to their MarketBeat watchlist in the last 30 days. This is a decrease of -43% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Insmed insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $5,765,446.00 in company stock.Percentage Held by InsidersOnly 4.60% of the stock of Insmed is held by insiders.Read more about Insmed's insider trading history. INSM Stock News HeadlinesInsider Selling: Insmed Incorporated (NASDAQ:INSM) Insider Sells 13,436 Shares of StockSeptember 17 at 4:29 AM | insidertrades.comInsmed Incorporated (NASDAQ:INSM) Insider Orlov S. Nicole Schaeffer Sells 37,575 SharesSeptember 11, 2024 | insidertrades.comBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial independence and security.September 18, 2024 | Golden Crest (Ad)Michael Alexander Smith Sells 27,871 Shares of Insmed Incorporated (NASDAQ:INSM) StockSeptember 18 at 6:59 AM | americanbankingnews.comInsmed Incorporated (NASDAQ:INSM) Insider Sells $1,006,625.12 in StockSeptember 18 at 4:25 AM | americanbankingnews.com(INSM) - Analyzing Insmed's Short InterestSeptember 17 at 2:45 PM | benzinga.comOrlov S. Nicole Schaeffer Sells 37,575 Shares of Insmed Incorporated (NASDAQ:INSM) StockSeptember 12, 2024 | americanbankingnews.comEvercore ISI Remains a Buy on Insmed (INSM)September 11, 2024 | markets.businessinsider.comSee More Headlines INSM Stock Analysis - Frequently Asked Questions How have INSM shares performed this year? Insmed's stock was trading at $30.99 at the beginning of 2024. Since then, INSM shares have increased by 135.1% and is now trading at $72.87. View the best growth stocks for 2024 here. How were Insmed's earnings last quarter? Insmed Incorporated (NASDAQ:INSM) released its quarterly earnings results on Thursday, August, 8th. The biopharmaceutical company reported ($1.94) EPS for the quarter, missing analysts' consensus estimates of ($1.22) by $0.72. The business's revenue for the quarter was up 17.0% compared to the same quarter last year. Who are Insmed's major shareholders? Insmed's top institutional shareholders include Darwin Global Management Ltd. (2.38%), William Blair Investment Management LLC (2.33%), Principal Financial Group Inc. (1.12%) and Clearbridge Investments LLC (1.11%). Insiders that own company stock include William Lewis, Melvin Md Sharoky, Roger Adsett, John Drayton Wise, Sara Bonstein, Martina MD Flammer, Orlov S Nicole Schaeffer, Michael Alexander Smith and David R Brennan. View institutional ownership trends. How do I buy shares of Insmed? Shares of INSM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Insmed own? Based on aggregate information from My MarketBeat watchlists, some other companies that Insmed investors own include Gilead Sciences (gild), AbbVie (ABBV), Johnson & Johnson (JNJ), NVIDIA (NVDA), Micron Technology (MU), ACADIA Pharmaceuticals (ACAD) and OPKO Health (OPK). Company Calendar Last Earnings8/08/2024Today9/18/2024Next Earnings (Estimated)10/24/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:INSM CUSIPN/A CIK1104506 Webwww.insmed.com Phone908-977-9900Fax732-438-0381Employees373Year FoundedN/APrice Target and Rating Average Stock Price Target$79.19 High Stock Price Target$102.00 Low Stock Price Target$42.00 Potential Upside/Downside+8.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage16 Analysts Profitability EPS (Most Recent Fiscal Year)($5.23) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-749,570,000.00 Net Margins-244.27% Pretax Margin-243.37% Return on EquityN/A Return on Assets-57.00% Debt Debt-to-Equity Ratio25.05 Current Ratio2.71 Quick Ratio2.53 Sales & Book Value Annual Sales$328.61 million Price / Sales32.95 Cash FlowN/A Price / Cash FlowN/A Book Value($2.32) per share Price / Book-31.41Miscellaneous Outstanding Shares148,605,000Free Float141,769,000Market Cap$10.83 billion OptionableOptionable Beta1.11 Social Links This page (NASDAQ:INSM) was last updated on 9/18/2024 by MarketBeat.com Staff From Our PartnersChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredThis diversified cannabis pioneer could make huge moves soonThe cannabis industry seems deeply saturated, so how do you know where to best invest your money? Let’s start ...Greenlane | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnlock the Secret to Easy Wins with Iron CondorsDiscover the power of Iron Condor trades – a low-risk, high-reward strategy that allows you to profit consiste...Netpicks | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored625,000% GainThe recent crypto correction has shaken many investors, causing panic and uncertainty. But while others are fr...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist My Default Watchlist Adding Insmed Incorporated You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Please log in to your account or sign up in order to add this asset to your watchlist. Share Insmed With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.